Samsung Biologics Co.,Ltd. (207940.KS)

KRW 959000.0

(-2.14%)

Operating Expenses Summary of Samsung Biologics Co.,Ltd.

Samsung Biologics Co.,Ltd.'s latest annual operating expenses in 2023 was 638.51 Billion KRW , up 432.34% from previous year.
Samsung Biologics Co.,Ltd.'s latest quarterly operating expenses in 2024 Q3 was 848.49 Billion KRW , down -71.55% from previous quarter.
Samsung Biologics Co.,Ltd. reported a annual operating expenses of 484.82 Billion KRW in annual operating expenses 2022, up 156.33% from previous year.
Samsung Biologics Co.,Ltd. reported a annual operating expenses of 189.14 Billion KRW in annual operating expenses 2021, up 53.41% from previous year.
Samsung Biologics Co.,Ltd. reported a quarterly operating expenses of 848.49 Billion KRW for 2024 Q3, down -71.55% from previous quarter.
Samsung Biologics Co.,Ltd. reported a quarterly operating expenses of 725.6 Billion KRW for 2024 Q1, up 0.29% from previous quarter.

Annual Operating Expenses Chart of Samsung Biologics Co.,Ltd. (2023 - 2014)

Historical Annual Operating Expenses of Samsung Biologics Co.,Ltd. (2023 - 2014)

Year	Operating Expenses	Operating Expenses Growth
2023	638.51 Billion KRW	432.34%
2022	484.82 Billion KRW	156.33%
2021	189.14 Billion KRW	53.41%
2020	123.28 Billion KRW	22.96%
2019	100.26 Billion KRW	12.05%
2018	89.48 Billion KRW	35.95%
2017	65.82 Billion KRW	15.56%
2016	56.95 Billion KRW	-68.38%
2015	180.13 Billion KRW	80.46%
2014	99.82 Billion KRW	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	722.39 Billion KRW	-0.44%
2024 Q3	848.49 Billion KRW	-71.55%
2024 Q1	725.6 Billion KRW	0.29%
2023 Q1	150.79 Billion KRW	-0.46%
2023 Q3	-183.28 Billion KRW	-5.51%
2023 Q2	-173.7 Billion KRW	-215.19%
2023 Q4	723.54 Billion KRW	494.77%
2023 FY	2580.9 Billion KRW	432.34%
2022 Q2	118.57 Billion KRW	122.41%
2022 FY	484.82 Billion KRW	156.33%
2022 Q4	151.5 Billion KRW	-6.15%
2022 Q3	161.43 Billion KRW	36.15%
2022 Q1	53.31 Billion KRW	-16.86%
2021 Q2	44.63 Billion KRW	35.03%
2021 FY	189.14 Billion KRW	53.41%
2021 Q4	64.12 Billion KRW	35.48%
2021 Q3	47.33 Billion KRW	6.05%
2021 Q1	33.05 Billion KRW	-24.35%
2020 Q4	43.69 Billion KRW	44.84%
2020 Q3	30.16 Billion KRW	20.93%
2020 Q1	24.49 Billion KRW	-2.53%
2020 FY	123.28 Billion KRW	22.96%
2020 Q2	24.94 Billion KRW	1.85%
2019 Q1	22.99 Billion KRW	-27.48%
2019 FY	100.26 Billion KRW	12.05%
2019 Q4	25.12 Billion KRW	-0.26%
2019 Q3	25.19 Billion KRW	-6.51%
2019 Q2	26.94 Billion KRW	17.16%
2018 Q2	19.28 Billion KRW	26.59%
2018 FY	89.48 Billion KRW	35.95%
2018 Q4	31.71 Billion KRW	36.42%
2018 Q3	23.24 Billion KRW	20.55%
2018 Q1	15.23 Billion KRW	-23.74%
2017 Q4	19.97 Billion KRW	19.79%
2017 Q1	14.29 Billion KRW	-17.99%
2017 FY	65.82 Billion KRW	15.56%
2017 Q2	14.87 Billion KRW	4.01%
2017 Q3	16.67 Billion KRW	12.13%
2016 Q3	14.84 Billion KRW	12.01%
2016 Q2	13.25 Billion KRW	16.09%
2016 Q4	17.43 Billion KRW	17.42%
2016 Q1	11.41 Billion KRW	0.0%
2016 FY	56.95 Billion KRW	-68.38%
2015 FY	180.13 Billion KRW	80.46%
2014 FY	99.82 Billion KRW	0.0%

Peer Operating Expenses Comparison of Samsung Biologics Co.,Ltd.

Name	Operating Expenses	Operating Expenses Difference
ORIENT BIO Inc.	10.23 Billion KRW	-6141.423%
Green Cross Holdings Corporation	620.02 Billion KRW	-2.984%
Green Cross Holdings Corporation	424.43 Billion KRW	-50.44%
Pharmicell Co., Ltd.	14 Billion KRW	-4459.488%
Green Cross Corporation	424.43 Billion KRW	-50.44%
GeneOne Life Science, Inc.	40.6 Billion KRW	-1472.367%
Celltrion, Inc.	359.46 Billion KRW	-77.629%
SK bioscience Co.,Ltd.	154.23 Billion KRW	-314.003%
SK Biopharmaceuticals Co., Ltd.	358.33 Billion KRW	-78.192%
Prestige BioPharma Limited	63.47 Billion KRW	-905.986%